{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Perspective Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"CATX"},"Address":{"label":"Address","value":"350 HILLS STREET,SUITE 106, RICHLAND, Washington, 99354, United States"},"Phone":{"label":"Phone","value":"+1 509 375-5329"},"Industry":{"label":"Industry","value":"Medical/Dental Instruments"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions."},"CompanyUrl":{"label":"Company Url","value":"https://www.perspectivetherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Hauser","title":"Senior Vice President-Clinical Operations"},{"name":"Johan M. Spoor","title":"Chief Executive Officer & Director"},{"name":"Markus Puhlmann","title":"Chief Medical Officer"},{"name":"Michael K. Schultz","title":"Chief Science Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}